<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97584">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02081157</url>
  </required_header>
  <id_info>
    <org_study_id>CP-1050</org_study_id>
    <nct_id>NCT02081157</nct_id>
  </id_info>
  <brief_title>Use of GalaFlex in Ptotic Breast</brief_title>
  <official_title>Use of GalaFlex in Ptotic Breast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galatea, Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galatea, Corp</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the physician preference in the clinical performance of the GalaFLEX
      mesh in soft tissue reinforcement during elective (cosmetic) plastic surgery to the breast,
      in particular the breast lift mastopexy and breast reduction procedures
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Investigator satisfaction with the surgical implantation/usage of GalaFLEX mesh in elective plastic surgery to the breast evaluated using a surgeon satisfaction questionnaire.</measure>
    <time_frame>1year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical Performance of the GalaFLEX mesh:  evaluation of the resolution of ptosis will be evaluated based on the change in nipple to IMF distance and sternal notch to nipple distance pre- and post-surgery.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>â€¢ Long term visibility:  Mammography and ultrasound will be used to evaluate the presence of the mesh or potential for mesh interference in evaluation of the breast tissue.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ptotic Breast</condition>
  <arm_group>
    <arm_group_label>Breast Mastopexy &amp;/or reduction using GalaFlex Mesh</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GalaFlex Mesh</intervention_name>
    <arm_group_label>Breast Mastopexy &amp;/or reduction using GalaFlex Mesh</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is able to understand the risks and benefits of participating in the study
             and must be willing to sign and date the Informed Consent Form for this study
             approved by the Institutional Review Board (IRB.)

          2. Be at least 21 years of age.

          3. Be willing and able to comply with the requirements of the protocol.

          4. Be willing to refrain from participating in any other investigational interventional
             study while enrolled in this study.

          5. Female subjects must have a negative pregnancy test within the last 24 hours timeline
             and have no intentions of becoming pregnant during participation in the study, or be
             sterilized.

        Exclusion Criteria:

          1. Subjects unwilling or unable to give written consent to participate in the
             investigation or unable to comply with the requirements of the protocol.

          2. Subjects with known severe allergies manifested by a history of anaphylaxis or
             allergy to GalaFLEX mesh, poly-4-hydroxybutyrate (P4HB), a resorbable polymer, or
             silicone.

          3. Subjects with known active infection and/or who received or are targeted to receive
             immunosuppressive therapy over the course of the study (such as rheumatoid
             arthritis).

          4. Subjects who received any experimental drug or device within the previous three
             months.

          5. Female subjects who were pregnant or lactating or were intending to become pregnant
             during the period of the study, or who would not use an adequate method of
             contraception (contraceptive pill, intra-uterine device) for the duration of the
             study.

          6. Possessed any psychological condition, or was under treatment for any condition
             which, in the opinion of the Investigator and/or consulting physicians(s), would
             constitute an unwarranted risk.

          7. Have collagen-vascular, connective disease, or bleeding disorders.

          8. Have a BMI that is greater than or equal to 30.

          9. Have any disease, including uncontrolled diabetes, which is clinically known to
             impact wound healing ability.

         10. Have an autoimmune disease, an immune deficiency, or is on immune suppression drugs.

         11. Currently have an alcohol/substance abuse problem or have had a relapse within 1 year
             prior to screening visit.

         12. Have concomitant unrelated condition of breast/chest wall/skin.

         13. Have undergone previous breast surgery with the exception of breast biopsy.

         14. Subject is currently a smoker or is a prior smoker who quit in the last 12 months.

         15. Currently involved with claims for, or is accepting workers compensation.

         16. Currently engaged in medical malpractice litigation.

             -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arikha Moses, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Tepha, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ponte Vedra Plastic Surgery</name>
      <address>
        <city>Ponte Verdra Beach</city>
        <state>Florida</state>
        <zip>32083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Plastic Surgeons</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Longwood Plastic Surgery</name>
      <address>
        <city>Brookline</city>
        <state>Massachusetts</state>
        <zip>02445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkcrest Plastic Surgical</name>
      <address>
        <city>Creve Coeur</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glicksman Plastic Surgery</name>
      <address>
        <city>Sea Girt</city>
        <state>New Jersey</state>
        <zip>08750</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York-Presbyterian Hospital, the University Hospital of Columbia and Cornell</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William P. Adams, M.D.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plastic Surgery Clinic</name>
      <address>
        <city>Mountlake Terrace</city>
        <state>Washington</state>
        <zip>98043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 5, 2014</lastchanged_date>
  <firstreceived_date>March 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
